Novo Nordisk (NOVOB.DK) shares are gaining 3.0% after the company raised its sales forecast for 2023 on strong demand for Ozempic and Wegovy medicines.
- Operating profit at constant exchange rates +40% to +46%, previously expected +31% to +37%, Bloomberg estimated +37.5%
- Sales at constant exchange rates +32% to +38%, previously expected +27% to +33%, Bloomberg estimated +31.7%.
Arista Networks Beats Expectations and Provides Fresh Support for the AI Investment Cycle
Market wrap (05.08.2026)
AMD Did Everything Right… But Only Right
SpaceX Shares Drop 6% After Earnings 🚩 Is Space No Longer Enough for Wall Street?